Comparison

XVA143 European Partner

Item no. HY-139202-1ea
Manufacturer MedChem Express
CASRN 264275-77-6
Amount 1 ea
Quantity options 100 mg 1 ea
Category
Type Molecules
Specific against other
Citations [1]Azucena Salas, et al. Rolling adhesion through an extended conformation of integrin alphaLbeta2 and relation to alpha I and beta I-like domain interaction. Immunity. 2004 Apr;20(4):393-406.
[2]Mélanie R Tardif, et al. LFA-1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T-20. Antimicrob Agents Chemother. 2009 Nov;53(11):4656-66.
Smiles O=C(O)[C@H](CNC(C1=CC(O)=CC(O)=C1)=O)NC(C2=C(Cl)C=C(C(NCC3=CC=CC(O)=C3)=O)C=C2Cl)=O
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
COVID-19-immunoregulation
Manufacturer - Targets
Integrin
Shipping Temperature
Room temperature
Molecular Weight
562.36
Product Description
XVA143, an α/β I-like allosteric antagonist, inhibits LFA-1 dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo[1].
Manufacturer - Research Area
Inflammation/Immunology
Solubility
10 mM in DMSO
Manufacturer - Pathway
Cytoskeleton
Clinical information
No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 ea
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close